18th week of 2009 patent applcation highlights part 39 |
Patent application number | Title | Published |
20090110677 | POLYPEPTIDE REGULATING PHOSPHATE METABOLISM, CALCIUM METABOLISM, CALCIFICATION AND VITAMIN D METABOLISM AND DNAS ENCODING THE SAME - A DNA, which encodes the following polypeptide (a), (b), (c) or (d):
| 2009-04-30 |
20090110678 | RECEPTOR ANTAGONISTS FOR TREATMENT OF METASTATIC BONE CANCER - The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents. | 2009-04-30 |
20090110679 | Methods and compositions for pulmonary administration of a TNFa inhibitor - The invention describes methods of pulmonary delivery of a TNFα inhibitor to a subject having a disorder in which TNFα is detrimental, such that the disorder is treated. Also included is a method of achieving systemic circulation of a TNFα inhibitor in a subject comprising administering the TNFα inhibitor to the central lung region or the peripheral lung region of the subject via inhalation, such that systemic circulation of the TNFα inhibitor is achieved. | 2009-04-30 |
20090110680 | Combination of an anti ED-B fibronectin domain antibody and gemcitabine - Disclosed is a combination of an anti edb fibronectin domain antibody and gemcitabine. | 2009-04-30 |
20090110681 | Anti-M-CSF Antibody Compositions - The present invention provides for compositions of anti-M-CSF antibodies comprising a chelating agent and/or histidine. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF anti-bodies, including inflammatory diseases and neoplasia disorders. | 2009-04-30 |
20090110682 | Antibody Having Inhibitory Effect on Amyloid Fibril Formation - Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided. | 2009-04-30 |
20090110683 | MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies. | 2009-04-30 |
20090110684 | Neutralizing monoclonal antibodies to respiratory syncytial virus - The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. | 2009-04-30 |
20090110685 | Treatment and prevention of viral infections - Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection. | 2009-04-30 |
20090110686 | Antibodies against CCR5 and uses thereof - An antibody binding to CCR5 characterized in that the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 1, and has advantageous properties for the treatment of immunosuppressive diseases. | 2009-04-30 |
20090110687 | COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 2009-04-30 |
20090110688 | COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 2009-04-30 |
20090110689 | IMMUNOSUPPRESSION COMPOUND AND TREATMENT METHOD - A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4. | 2009-04-30 |
20090110690 | Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens - The present disclosure relates to stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, to crystalline forms of the stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, and to the high resolution structure obtained from these crystals by X-ray diffraction methods. Methods for identifying immunogenic polypeptides based on these structures are also disclosed. | 2009-04-30 |
20090110691 | Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - The invention provides | 2009-04-30 |
20090110692 | ISOLATED COMPLEXES OF ENDOTOXIN AND MODIFIED MD-2 - Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2. | 2009-04-30 |
20090110693 | MULTIMERIC COMPLEXES OF ANTIGENS AND AN ADJUVANT - The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines. | 2009-04-30 |
20090110694 | Anti-Inflammatory Proteins and Improved Vaccines - A recombinant poxvirus lacking a functional gene corresponding to BI4R in the WR strain of VACV for use as a medicament especially as a vaccine against a disease caused by a poxvirus or another pathogenic agent or for use as a medicament against a disease associated with aberrant cells. An isolated nucleotide or polypeptide encoding a poxvirus sequence corresponding to the sequence of B14 in the WR strain of VACV especially for use as a medicament against undesirable inflammation, immune activation or NF-κB activation. Related compositions and methods. | 2009-04-30 |
20090110695 | Compositions Comprising a Recombinant Adenovirus and an Adjuvant - The invention relates to pharmaceutical compositions comprising replication-defective adenoviruses, said adenoviruses generally comprising an adenoviral genome wherein a heterologous nucleic acid of interest is incorporated, and wherein said nucleic acid typically encodes an antigen. Such compositions are suitable for vaccination purposes. The pharmaceutical compositions of the present invention further comprise an adjuvant, which stimulates and increases the immune response towards the antigen encoded by the heterologous nucleic acid. Preferred adjuvants are oil-emulsion based adjuvants and aluminium-based adjuvants. | 2009-04-30 |
20090110696 | Mycobacterial SecA2 Mutants - Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not | 2009-04-30 |
20090110697 | INACTIVATED BOVINE HERPES VIRUS-1 AND METHODS - This invention related to a method of immunizing cattle to reduce the effects of infection by bovine herpes virus 1, including abortion and stillbirth, by administering inactivated bovine herpes virus 1 prior to breeding. | 2009-04-30 |
20090110698 | METHOD OF DETERMINING VACCINE COMPLIANCE - A protein (xylanase) has been identified that produces a strong immune response in pigs when added to a vaccine. The protein is added to vaccines at a particular concentration. The protein is delivered to the animal as part of the vaccine and elicits an immune reaction (antibodies are generated by the animal against the compliance marker protein). The antibodies are then detected in sera samples by a diagnostic test, enzyme-linked immunosorbent assay (ELISA). In the ELISA compliance marker assay, the marker protein (antigen) in coated onto polystyrene plates and is used to detect antibodies against the marker in sera samples. This combination of marker protein added to vaccines and the ELISA to detect antibodies raised against the marker protein can be used to determine whether a particular animal(s) has been vaccinated. The selected protein is commercially-available, identified as Generally Recognized as Safe by the FDA, and does not cause adverse reactions in animals. | 2009-04-30 |
20090110699 | Antigen-Adjuvant Compositions and Methods - Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to mammals and methods for eliciting an immune response in mammals by administering the compositions. | 2009-04-30 |
20090110700 | ACELLULAR IMMUNOGENIC COMPOSITIONS AND ACELLULAR VACCINE COMPOSITIONS AGAINST BACILLUS ANTHRACIS - The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against | 2009-04-30 |
20090110701 | T-CELL MODULATION - The invention provides methods and materials for use in modulating T cell activation, based on the production and secretion of soluble cytotoxic T-lymphocyte antigen-4 (sCTLA-4) by cells of the immune system. The method involves stimulating secretion of endogenous sCTLA-4 by T cells, which have preferably previously been exposed to an antigen, by exposing the said cells to a stimulatory agent, preferably a peptide which comprises at least one antigenic determinant of said antigen. The cells may also be exposed to a CD28 stimulatory binding agent, either alone or in combination with the antigenic peptide. In preferred embodiments, the method may be used for treatment or prophylaxis of a disease characterized by a pathogenic immune or autoimmune response. The invention also provides a system for inhibiting sCTLA-4 secretion by T cells. | 2009-04-30 |
20090110702 | Mesothelin Vaccines and Model Systems and Control of Tumors - Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line. | 2009-04-30 |
20090110703 | Cosmetic composition comprising polyorganosiloxane and uses thereof - The invention relates to a cosmetic composition comprising a cosmetically acceptable vector and polyorganosiloxane. The polyorganosiloxane comprises a group that includes a sterically hindered amine. | 2009-04-30 |
20090110704 | COSMETIC COMPOSITION BASED ON A MAGNETIC OR MAGNETISABLE MATERIAL, THE PREPARATION THEREOF AND USE THEREOF FOR CLEANSING THE EPIDERMIS - The present invention relates to a cosmetic composition based on a magnetic or magnetisable material, the preparation thereof and use thereof for surface and deep cleansing of the epidermis. Said cosmetic composition has revealed to be particularly useful for preparing a mask for cleansing the epidermis of the face, breast, hands and body and, simultaneously, for maintaining the aesthetic appearance and functional efficiency thereof. | 2009-04-30 |
20090110705 | MOISTURIZERS COMPRISING ONE OR MORE OF gamma-POLYGLUTAMIC ACID (gamma-PGA, H FORM), gamma-POLYGLUTAMATES AND gamma-POLYGLUTAMATE HYDROGELS FOR USE IN COSMETIC OR PERSONAL CARE PRODUCTS - The present invention relates to a moisturizer comprising γ-polyglutamic acid (γ-PGA, H form), and/or one or more of its salts (i.e., γ-polyglutamate in Na | 2009-04-30 |
20090110706 | PAIN RELIEF COMPOSITION AND UTILIZATION THEREOF - A titanium-impregnated tape uses a material treated by fine dispersion water containing citric acid or its salt in which fine metal titanium particles are dispersed. The titanium-impregnated tape provides a physiological structure that acts upon the function to interfere with the pain memory system affecting neurons. | 2009-04-30 |
20090110707 | Methods for Producing Pesticide Compositions - Disclosed are compositions and methods related to powder and granular emulsifiable concentrate pesticide formulations. As disclosed, emulsions from non-aqueous based liquid or solvent soluble pesticide actives may be prepared using a high purity, high molecular weight sulfonated lignin as the emulsion stabilizer. The resulting emulsions may then be dried to obtain a powder or granular emulsion concentrate where the high molecular weight sulfonated lignin acts as a solid matrix for the pesticide active. The powder or granular emulsifiable concentrate formulations thus formed have high loading rates, good storage properties and are easily reconstituted when added to water. | 2009-04-30 |
20090110708 | ANIMATE TISSUE ANTISEPSIS - A method and device provide for inactivating microorganisms on tissue exposed through a surgical incision. The method includes the steps of: applying a coating of a solution comprising hydrogen peroxide to the tissue; and force drying the solution on the tissue so as to concentrate the solution on the tissue. The concentrated solution kills microorganisms. | 2009-04-30 |
20090110709 | ELASTIN PROTECTIVE POLYPHENOLICS AND METHODS OF USING THE SAME - Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers. | 2009-04-30 |
20090110710 | DEVICES AND METHODS FOR TREATING DEFECTS IN THE TISSUE OF A LIVING BEING - An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may be “matched” to provide the implant with similar physical and/or chemical properties as the host tissue. | 2009-04-30 |
20090110711 | IMPLANTABLE DEVICE HAVING A SLOW DISSOLVING POLYMER - The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same. | 2009-04-30 |
20090110712 | Methods and systems for use of photolyzable nitric oxide donors - The present disclosure relates to methods and systems for use of photolyzable nitric oxide donors for the treatment of sexual dysfunction. | 2009-04-30 |
20090110713 | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices - The present invention is directed to polymeric materials (e.g., coatings) comprising biodegradable copolymers and implantable devices (e.g., drug-delivery stents) formed of such materials. The biodegradable copolymers are derived from at least two relatively polar monomers and at least one relatively nonpolar monomer. Incorporation of at least one relatively nonpolar monomer into the copolymer improves controlled release of a hydrophobic drug from the polymeric material by increasing the copolymer's miscibility with and permeability to the hydrophobic drug. The polymeric materials can also contain at least one biocompatible moiety, at least one non-fouling moiety, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric materials are designed to improve the mechanical, physical and biological properties of implantable devices formed thereof. | 2009-04-30 |
20090110714 | Medical or veterinary digestive tract utilization systems and methods - Systems and methods are described for implementing or deploying medical or veterinary utility modules comprising a first module operable in a digestive or respiratory tract to engage a second module, optionally by a magnetic field. Alternatively or additionally, systems may be operable to remain in situ and also operable to permit a therapeutic material dispensation. In some contexts, for example, systems or methods may dispense a therapeutic material via a subject's throat or elsewhere in the digestive or respiratory tract. | 2009-04-30 |
20090110715 | Edible film Package Having Product for Oral Intake Enclosed Therein - This invention aims to provide a novel taking or having-or-swallowing form for an oral material, such as drugs or foodstuffs. | 2009-04-30 |
20090110716 | ORALLY DISINTEGRATIVE DOSAGE FORM - The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C. | 2009-04-30 |
20090110717 | TRANSMUCOSAL COMPOSITION - The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk ( | 2009-04-30 |
20090110718 | Derivatives of tiacumicin B as anti-cancer agents - New derivatives of tiacumicin B are disclosed and are presented by the general formula: | 2009-04-30 |
20090110719 | Polyamine modified particles - A particle composition comprising a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer, and a combinatorial delivery polymer comprising a plurality of particles that comprises a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer, a plurality of nucleic acids electrostatically loaded onto the particles, a plurality of chemokine molecules, and a biodegradable polymer network, in which the loaded particles and chemokine molecules may be entrapped, are disclosed. Also disclosed is a method for treating a subject comprising administering a therapeutically effective dose of a pharmaceutical composition, the pharmaceutical composition comprising a particle composition that comprises a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer. | 2009-04-30 |
20090110720 | Use of compounds for the prevention of drug-induced cell toxicity - The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephewrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment, the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of docking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds. | 2009-04-30 |
20090110721 | Paneled capsule shells for release of pharmaceutical compositions - Capsule shells for use in multi-part dosage forms have generally cylindrical shell members with a snap fit component on an interior surface adjacent an open end, for connection to a linker part of the dosage form. The shell member also has a plurality of spaced apart integrally formed thin (relative to circumferentially adjacent shell member portions) panels located adjacent a closed shell member end, for preferential dissolution and release of pharmaceutical compositions from the shell member interior. The ratio of the thickness of the panels to the thickness of the shell member ranges from about 0.2 to about 0.6. The panels can be integrally formed together with the shell member as reliefs or depressions on the inner surface of the shell member by injection molding, and panel thicknesses as thin as about 0.1 mm can be achieved, | 2009-04-30 |
20090110722 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 2009-04-30 |
20090110723 | Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms - A linker for multicomponent dosage form has a preformed drug substance tablet and an injection molded jacket including one or both axial jacket ends open for dispensing the preformed drug substances. The jacket has snap-fit connection elements on the outer surface adjacent each end for engagement with complementary snap-fit element on capsule-type and cap-type dosage form units. Another multicomponent drug form linker is injection molded with a raised circumferential band and snap-fit elements between the band and respective ends engageable with complementary snap-fit elements on dosage form units to provide compressive abutting contact between ends of the units and the band. The band can have an axially tapered outer surface to accommodate dosage form units of different diameters. Still another multicomponent dosage form linker has separable male and female parts each engageable with, and separately sealing, respective dosage form units to be linked. Circumferential complementary grooves, groove segments, ridges and ridge segment-type snap-fit elements are disclosed, as are dosage forms using the above-described linkers. | 2009-04-30 |
20090110724 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention relates to compositions and methods for treatment of various forms of pain. Specifically, the method involves administering to a patient a composition comprising butalbital, acetaminophen and caffeine in the gelcap dosage form, to treat and/or alleviate the occurrence or negative effects of various forms of headaches. | 2009-04-30 |
20090110725 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 2009-04-30 |
20090110726 | FORMULATION HAVING ACCURATE DOSE-DIVIDING FUNCTION - The present invention provides a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, and having a scored line capable of dividing the whole tablet on the connecting part; particularly, a coated tablet in which a connecting part and a coating layer have the same or different drug release controlling functions; a tablet having an insoluble coating on a drug-containing part having a scored line, wherein the drug-containing part has a structure or composition such that the drug is substantially released after the tablet is divided along the scored line and then ingested; and a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, wherein at least two drug-containing parts have different compositions. | 2009-04-30 |
20090110727 | Extended release compositions of proton pump inhibitors - The invention provides extended release compositions comprising at least one proton pump inhibitor. The invention also provides methods for treating gastrointestinal disorders by administering the compositions of the invention to patients in need of gastrointestinal therapy. | 2009-04-30 |
20090110728 | Zero-Order Modified Release Solid Dosage Forms - The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic material, and a coating containing a hydrophilic pore-forming agent and a hydrophobic polymer. The dosage form exhibits a zero-order release profile upon dissolution. | 2009-04-30 |
20090110729 | SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM - This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. | 2009-04-30 |
20090110730 | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same - The present invention relates to the use of certain microspheres, nanospheres, and other structures to provide a method of marking or masking identifying marks in individual biological hosts. Biological hosts for the present invention may include humans, other animals, or plants. Such methods may be used to sense, signal, track, mark, or identify individual biological hosts. Microspheres, nanospheres, and other structures of the present invention may be implanted, injected, ingested, or attached to individual biological hosts. Microspheres, nanospheres, and other structures of the present invention comprise poly[bis(trifluoroethoxy)phosphazene] and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The microspheres, nanospheres, and other structures may also comprise a core having a hydrogel which may further comprise one or more dyes or other chromophoric agents covalently bound permanently to the hydrogel core material. The microspheres, nanospheres, and other structures and/or the hydrogel core may further comprise radio frequency or other electronic chips or nanochips, capable of transmitting and/or receiving electronic signals from external transmitters and/or receivers. | 2009-04-30 |
20090110731 | Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same - Particles are provided for use in restorative procedures to treat and/or retard alopecia The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in various colors or with customized coloration to match desired scalp colors. Moreover, such particles may be loaded to provide localized treatment with an active component agent directed at restoration of normal function and hair production within the hair follicle. | 2009-04-30 |
20090110732 | BIORESORBABLE COMPOSITION FOR REPAIRING SKELETAL TISSUE - Bioresorbable compositions for treating skeletal tissue are disclosed. The biomedical compositions are formed from a polylactide polymer, a polyglycolide polymer, or a poly(lactic-co-glycolic acid) polymer having a relatively low molecular weight. For instance, the average number molecular weight of the polymer is generally less than 10,000, such as from about 500 to about 5,000. Fumarate groups are incorporated into the low molecular weight polymer that provide crosslinking sites. If desired, ethylene oxide groups and ceramic particles may also be incorporated into the polymer for producing compositions having a variety of properties. For example, the biomedical composition of the present disclosure can be used to treat soft skeletal tissue or to treat hard skeletal tissue. The biomedical compositions are biodegradable and can contain various therapeutic, beneficial and pharmaceutical agents that may be released during degradation of the polymer. | 2009-04-30 |
20090110733 | DELIVERY MEANS - A delivery means for delivering a deliverable material to a wound bed comprises a hydrogel (preferably an optionally cross-linked polyvinylalcohol) and a deliverable material comprising: (i) a decomposable material which in the absence of said hydrogel decomposes and/or is permanently denatured if sterilised using heat, electron beam radiation or gamma radiation; (ii) a protein, protein fragment, peptide or amino acid; or (iii) a secretion or excretion from the organism | 2009-04-30 |
20090110734 | QUATERNISED AMMONIUM CYCLODEXTRIN COMPOUNDS - Use of a compound of formula (I): | 2009-04-30 |
20090110735 | CONTROLLED RELEASE FORMULATIONS - The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body. | 2009-04-30 |
20090110736 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2009-04-30 |
20090110737 | Orally Disintegrating Powder Comprising Cilostazol and Mannitol - The present invention provides an orally disintegrating powder comprising cilostazol as an active ingredient and mannitol in an amount of 70% by weight or more, which can be taken without water and can be disintegrated in oral cavity. Said powder is suitable for patients to whom cilostazol is applied, especially for aged patients and patients suffering from dysphagia. | 2009-04-30 |
20090110738 | Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same - Particles are provided for use in therapeutic cosmetic and/or reconstructive procedures to augment defects in tissue to restore contours and/or function. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in various colors or with customized coloration to match desired tissues. Moreover, such particles may be loaded to provide localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided or used in conjunction with tissue adhesives or photoinitiator agents that may be activated by electromagnetic radiation or other energy sources to allow post-implantation cross-linking of the polymeric particles to cause their amalgamation to maintain their shape and location following implantation. | 2009-04-30 |
20090110739 | Targeted cancer chemotherapy using synthetic nanoparticles - Compositions and methods for delivery of a pharmaceutical to an individual. Delivery vehicles are provided in a formulation of a pharmaceutical that is encapsulated in a synthetic self assembled nanoparticle that includes a lipid binding protein and a lipid monolayer. The interior of the particle represents a hydrophobic core region where lipophilic highly-water insoluble drug molecules may be incorporated. In contrast to liposomes, that include an aqueous interior core surrounded by phospholipid bilayer, the drug carrier nanoparticle described here is composed of a monolayer and a hydrophobic interior. | 2009-04-30 |
20090110740 | Materials and Methods for Modulating Metabolism - The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications. | 2009-04-30 |
20090110741 | METHOD AND COMPOSITIONS FOR POLYMER NANOCARRIERS CONTAINING THERAPEUTIC MOLECULES - A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of the amphiphilic diblock copolymer and a protein having a molecular weight of up to or equal to 300,000 Da. Selection of the hydrophobic polymer block percentage alters one or more characteristics of the resulting nanoparticles, such as shape. Thus, as one aspect, a method of producing filamentous polymeric nanocarrier-encapsulated protein (i.e., active enzyme) particles involves forming a primary emulsion using a freeze-thaw cycle of (i) an amphiphilic diblock copolymer, which has a molecular weight of about 10,000 to about 100,000 Da and comprises a conjugate of the hydrophobic polymer block and a hydrophilic polymer block, wherein the amphiphilic diblock copolymer comprises greater than 81% to about 95% by weight of the hydrophobic polymer block; and a protein having a molecular weight of up to or equal to about 300,000 Da. Various compositions comprising such filamentous-shaped nanocarrier particles, and methods of use for diagnosis and therapy are disclosed. | 2009-04-30 |
20090110742 | Long-acting colloidal insulin formulation and its preparation - The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. | 2009-04-30 |
20090110743 | Porous beta-tricalcium phosphate granules and methods for producing same - A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous β-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous β-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous β-TCP material and inducing bone formation are also provided. | 2009-04-30 |
20090110744 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS - A sustained release microsphere composition comprising—
| 2009-04-30 |
20090110745 | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging - The present invention provides methods for improving cognitive function, improving mood, and decreasing aggression in a normal adult subject, and in a subject having symptoms characteristic of a neurological disorder, by administration of a nutriceutical formulation of the invention to the subject. The invention additionally features methods of treating neurological disorders, depression, and aggression using nutriceutical formulations. Nutriceutical compositions and formulations for use in the methods of the invention, and kits containing nutriceutical compositions and formulations, are also provided. | 2009-04-30 |
20090110746 | New class of therapeutics that enhance small modecule diffusion - The subject invention relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders. | 2009-04-30 |
20090110747 | DRUG AND/OR FOOD SUPPLEMENT CONTAINING NISYLEN R, CEPA, EUPHRASIA, BELLADONA AND/OR MERCURIUS SOLUBILIS - The present disclosure relates to a drug and/or food supplement with antiviral effects, in particular for the preventive and/or therapeutic treatment of herpes labialis and/or herpes genitalis, and/or with antibacterial and/or immunomodulating and/or antiphlogistic effects and/or for the preventive and/or therapeutic treatment of affections of the prostate, containing NISYLEN® and/or Cepa and/or Euphrasia and/or Belladonna and/or Mercurius solubilis. | 2009-04-30 |
20090110748 | Biocompatible Material and Process for Manufacturing the Same - In order to provide a biocompatible material consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen, which is adjusted so that easily digested and absorbed in a human body, the material contains a composite consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen. | 2009-04-30 |
20090110749 | Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic - An improved method and apparatus is disclosed for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting solution is balanced to normal and hypertonic saline and has been shown to exhibit remarkable antimicrobial, antiviral and therapeutic characteristics. The nature of this solution makes it suitable for applications in food safety, animal health, agriculture and sterilization. The solution also exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals. The therapeutic applications represent a broad platform, possibly covering a variety of potential areas of use, including topical disinfection, antimicrobial application, wound treatment, oxidative stress reduction and enhancement of immune function to better detect malfunctioning cells. | 2009-04-30 |
20090110750 | Antimicrobial Materials - A material for the treatment or prophylaxis of microbial, including bacterial, infections, comprising a metal species and a polymer, wherein the polymer stabilises the metal species. Compositions and devices comprising the material. A method for the treatment or prophylaxis of microbial, including bacterial, infections, comprising the use of such a material, composition or device. | 2009-04-30 |
20090110751 | Compositions and Methods for Treatment of Diseases of the Foot of an Animal - The present invention is directed to an activator composition comprising copper sulfate, zinc sulfate, sodium chloride, and ammonium sulfate, for the activation of an anti-microbial composition. The resulting activated anti-microbial composition is used for the treatment of an infectious disease of a foot of an animal, particularly for the use of ungulates. Benefits of using the activator composition, either alone or in conjunction with other anti-microbial compositions, include the reduction of copper deposited into the environment from anti-microbial treatments, extended use of an anti-microbial composition, and maintenance of low levels of infectious diseases of the feet of animals. | 2009-04-30 |
20090110752 | COMPOSITION FOR CONTROLLING BLOOD GLUCOSE AND METHOD THEREOF - A composition for controlling a blood glucose and a method thereof are provided. The composition comprises a far-infrared ray releasing substance, wherein the composition reduces the blood glucose of a subject via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of providing a far-infrared ray releasing substance having an oxide mineral as a main component, and disposing the far-infrared ray releasing substance in a place close to a subject in an appropriate distance, wherein the subject has an insulin resistance and the appropriate distance is within an irradiation range of the far infrared ray. | 2009-04-30 |
20090110753 | Enzyme-cleavable prodrug compounds - The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention. | 2009-04-30 |
20090110754 | Stabilized Chlorine Dioxide and Hypochlorous Acid in a Liquid Biocide - A liquid biocide containing stabilized chlorine dioxide and hypochlorous acid for various uses, including use as a teat dip or dairy animals. The stable, prophylactic biocide consists essentially of 0.10-20.0% by weight of a chlorite salt, 0.1-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water. Chlorite salt reacts with the acid to form germicidal chlorine dioxide and hypochlorous acid. The acid constituency and the alkaline agent constituency regulate the pH of the solution such that the biocide is stable when mixed for a period greater than two months. The present disclosure also includes a method of producing a stable, prophylactic biocide for dairy cattle, the method comprising 0.10-20.0% by weight of a chlorite salt, 0.10-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water in a container, and sealing the container. In the method, the acid and alkaline agent constituencies regulate the pH of the solution such that the formation of hydronium ions from the acid is correspondingly regulated to stabilize the solution for a period greater than two months from the date of sealing. | 2009-04-30 |
20090110755 | Compositions and Methods for Preventing Migraines - The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases. | 2009-04-30 |
20090110756 | Methods and Compositions Related to PLUNC Surfactant Polypeptides - Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide. | 2009-04-30 |
20090110757 | Methods for modulating eicosanoid metabolism - The inventive subject matter relates to methods for treating prostate cancer, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, | 2009-04-30 |
20090110758 | COMPOSITIONS AND METHODS FOR PROMOTING WEIGHT LOSS - Compositions, which include psyllium and polyethylene glycol in a weight ratio of psyllium to polyethylene glycol of from about 1:3 to about 2:1, a gum, and one or more additional ingredients selected from the group consisting of water, salt, sweeteners, flavoring agents, and preservatives are presented. | 2009-04-30 |
20090110759 | Pharmaceutical Composition for Use as a Laxative - The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like. | 2009-04-30 |
20090110760 | Lipometabolism improver containing pine bark extract - As a lipid metabolism improving agent for allowing lipids in the body to be metabolized efficiently, a lipid metabolism improving agent containing a pine bark extract as an active component is provided. The lipid metabolism improving agent of the present invention has abilities to promote cholesterol excretion, inhibit lipid absorption, reduce body fat, and inhibit fat accumulation, and the like. | 2009-04-30 |
20090110761 | Extrusion Molding Apparatus for Resin Tube - The dimensions of a tube molded by an extrusion molding apparatus are made more accurate. The arrangement of the extrusion molding apparatus enabling the molding of the aforesaid accurate tube is simplified. The molding of the aforesaid accurate tube is facilitated. The extrusion molding apparatus ( | 2009-04-30 |
20090110762 | Hot runner having reduced valve-stem drool - Disclosed is a valve-gated hot-runner system, having: (i) a back-up sealing arrangement, including: (i) a plurality of radial gaps associated with a valve stem of a valve actuator, and (ii) a cooling system being positioned relative to the plurality of radial gaps, the cooling system being configured to freeze a drool being made to enter, under pressure, into the plurality of radial gaps, so that the drool that becomes frozen substantially reduces flow of the drool along the valve stem and toward the valve actuator. | 2009-04-30 |
20090110763 | Material Delivery Tension and Tracking System for Use in Solid Imaging - A solid imaging apparatus and method employing a radiation transparent build material carrier and a build material dispensing system that accurately controls the thickness of the transferred layer of solidifiable liquid build material to the radiation transparent build material carrier to achieve high resolution imaging in three-dimensional objects built using an electro-optical radiation source. | 2009-04-30 |
20090110764 | REPLACEABLE DOUBLE-PLATE-INJECTION MOLD - A replaceable double-plate-injection mold comprises a movable side mold plate having one side formed with a male mold core; a movable side assembly plate being connected to another side of the movable side mold plate; a fixed side mold plate having one side being formed with a female mold core; and a fixed side assembly plate having one side installed with a plurality of track supporting rods for passing through the fixed side mold plate, the movable side mold plate, and the movable side assembly plate. One side of the fixed side assembly plate is recessed for assembling a supporting plate of the male mold core; and another side thereof is corresponding to the fixed side assembly plate. A center of the movable side mold plate is formed with a receiving portion. | 2009-04-30 |
20090110765 | Hot runner nozzle system - Disclosed is a hot-runner nozzle system, including: (i) a nozzle housing being configured to convey a molten molding material, (ii) a sieve being coupled with the nozzle housing, (iii) a nozzle tip being securely coupled relative to the sieve, and (iv) a retainer securely extending from the sieve, the retainer connecting with the nozzle tip. | 2009-04-30 |
20090110766 | Coupling for Pelleting Mill - A pelleting die assembly includes a tubular die that is rotated by a quill flange. During rotation, particulate material inside the tubular die is extruded through extrusion holes by rollers inside the tubular die. The die is coupled to the quill flange by a flat, annular disc having one side attached to the die by bolts and an opposite side attached to the quill flange by other bolts. The bolts extend axially through the annular disc and face in opposite directions. The annular disc may include grooves to allow cyclic deflection of the die in a radially outward direction while reducing cyclic loading and strain on the quill flange. | 2009-04-30 |
20090110767 | MOLD FOR INJECTION MOLDING - A mold for injection molding includes a male mold portion, and a female mold portion mating with the male mold portion to define a parting face therebetween. The female mold includes a mold cavity defined at the parting face, an injection aperture communicated with the mold cavity, an air channel defined at the parting face and evenly spaced from and partially surrounding the mold cavity, a spacing portion formed between the mold cavity and the air channel, and a gap formed between the male mold portion and the spacing portion for transmitting air from the mold cavity to the air channel during injection of molten plastic. When injecting molten plastic, air in the mold cavity can be expelled in time under pressure of the molten plastic and through the air channel. Therefore, the surface quality of the molded product can be improved, by avoiding formation of air holes, fissure. | 2009-04-30 |
20090110768 | Microbiocidal Control in the Processing of Meat-Producing Four-Legged Animals - Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise: I) contacting exterior surfaces of the live animal at least once with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one 1,3-dibromo-5,5-dialkylhydantoin, such contacting occurring at least once when the animal is en route to being slaughtered but before it is killed by exsanguination; or II) contacting the carcass of the animal, after exsanguination, with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one 1,3-dibromo-5,5-dialkylhydantoin or III) contacting at least one raw meat product and/or at least one processed meat product derived from the carcass. The contacting can be done one or more times in each of I), II), and III). Considerable advantages, which are described, are realized when using such methods. | 2009-04-30 |
20090110769 | Process for Producing Fermented Beverages Using Fermentation Raw Material Solutions of Low Maltotriose Ratio - It is an object of the present invention to provide fermented beverages that give no sweetness in aftertaste and which have less off-flavors by a technique that will not affect the principal taste and aroma characteristics and which is highly acceptable to consumers. | 2009-04-30 |
20090110770 | Galactosidase With Alpha-Galactosyltransferase Activity - The present invention concerns a β-galactosidase with transgalactosylating activity isolated from | 2009-04-30 |
20090110771 | SUGAR FREE LOW CALORIE SYRUP AND THE MANUFACTURING METHOD THEREOF - The invention concerns sugar-free syrup of low calories and a method of producing the same, which syrup is of low calories and is a healthy substitute of sugar because it has almost no calories but contains a lot of edible fiber. To this end, the sugar-free syrup of low calories according to one aspect of the invention is characterized in that it consists of 100 parts by weight of water-soluble edible fiber, 100 to 200 parts by weight of water, 0.2 to 2 parts by weight of gum, 0.2 to 2 parts by weight of natural stabilizer and a proper amount of sweetener. Also, a method of producing the sugar-free syrup of low calories according to another aspect of the invention is characterized in that it comprises the steps of adding 100 to 200 parts by weight of water to 100 parts by weight of water-soluble, edible fiber and then dissolving the mixture at 50° C. to 80° C. while agitating it, adding 0.2 to 2 parts by weight of gum when the water-soluble fiber is fully dissolved, and then dissolving the mixture while agitating it, adding 0.2 to 2 parts by weight of natural stabilizer when the gum is fully dissolved, and dissolving the mixture while agitating it, adding a proper amount of sweetener to the mixture and dissolving the resulting mixture, and then cooling it by placing the mixture at a room temperature | 2009-04-30 |
20090110772 | WATER SOLUBILIZATION OF CELLULOSICS AND RELATED COMPOUNDS - The present invention is directed toward a method of solubilizing melaninic, ligninic, chitinic, and/or cellulosic material. The method includes providing melaninic, ligninic, chitinic, and/or cellulosic material and providing an oxoacid ester of phosphorus or a mixture of an oxoacid of phosphorus and an alcohol. A blend of the melaninic, ligninic, chitinic, and/or cellulosic material, the oxoacid ester of phosphorus or the mixture of the oxoacid of phosphorus and alcohol is formed. The blend is then treated under conditions effective to solubilize the melaninic, ligninic, chitinic, and/or cellulosic material. | 2009-04-30 |
20090110773 | Fruit Snack with Probiotics and Method of Manufacturing a Fruit Snack with Probiotics - A fruit snack with probiotics that is stable at room temperature is manufactured by combining various ingredients including fruit juices/purees to produce a slurry and cooking the slurry to produce a center that contains a high moisture content. The fruit snack center is covered with a barrier layer which in turn is covered by an outer layer that contains heat sensitive ingredients, such as probiotic cultures. The barrier layer substantially prevents migration of moisture from the center to the outer layer, and the fruit snack is cooled prior to applying the outer layer to minimize damage/harm to the heat sensitive ingredients. In addition to including probiotic cultures and being stable at room temperature, the fruit snack has other desirable characteristics including a chewy soft texture and fruit-flavorings, and may be manufactured using traditional processes. | 2009-04-30 |
20090110774 | HIGH ANTIOXIDANT LEVELS IN COCOA-BASED BEVERAGES - The invention provides, in one aspect, a method of producing a ready-to-drink cocoa beverage containing high levels of beneficial cocoa polyphenols in a milk or soymilk base. The method incorporates an ultra high temperature treatment followed by a homogenization step. Cocoa powder levels can be selected from about 3.5% to about 10% by weight, while the mouthfeel, solution stability over time, and taste remain acceptable. | 2009-04-30 |
20090110775 | DISPOSABLE CARTRIDGE FOR USE IN A BEVERAGE MAKER, COMPRISING A NOVABLY ARRANGED NEEDLE MEMBER - A disposable cartridge ( | 2009-04-30 |
20090110776 | STAND-ALONE HOT-PREPARATION DEVICE FOR CONVENIENCE FOOD PRODUCTS, PARTICULARLY INSTANT HOT BEVERAGE MAKER - A stand-alone hot-preparation device for convenience food products, particularly instant beverage maker, includes
| 2009-04-30 |